Dan Peer

Dr. Dan Peer is the director of the Laboratory of Precision NanoMedicine at Tel Aviv University. He is also the Vice President for Research and Development at Tel Aviv University. His lab works in the interface of basic and translational science. In addition, Prof. Peer is the Founder and Managing Director of the SPARK Tel Aviv, Center for Translational Medicine. Moreover, Prof. Peer is on the Scientific Advisory Board of numerous international companies and an invited keynote speaker in many conferences. Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference for drug discovery in immune cells. In addition, his lab was the first to show systemic, cell- specific delivery of modified mRNA expressing therapeutic proteins that has enormous implications in cancer, inflammation and infectious diseases. Prof. Peer is one of the pioneers in the use of molecular medicines (gene silencing, gene expression and gene editing) for therapeutics and diseases management.

Lab Information

The Laboratory of Precision NanoMedicine, Tel Aviv University

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Genome editing approaches for in vivo gene therapy 0 RNAs vaccines (mRNA, cirRNA, and saRNA) 0 In vivo drug discovery 0 Tumor cells 0 Nanoparticles 0


  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)

This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More

This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More

IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More

"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More

In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More

The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More

This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More

The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More

The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More

  1. Rosenblum D, Gutkin A, Kedmi K, Ramishetti S, Veiga N, Jacobi A.M, Schubert M.S, Friedmann- Morvinski D, Cohen Z.R, Behlke M.A, Liberman J, Peer D. (2020) CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances: EABC9450.

  2. Uebbing L, Ziller A, Siewert C, Schroer M.A, Blanchet C.E, Svergun D.I, Ramishetti S, Peer D, Sahin U, Haas H and Langguth P. (2020 ) Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. Langmuir.

  3. Nogueira S, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer M.A., Blanchet C.E, Svergun D, Ramishetti R, Peer D, Langguth P, Sahin U, and Haas H. (2020) Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Applied NanoMaterials.

  4. Kon E, Hazan-Halevy I, Rosenblum D, Cohen N, Chatterjee S, Veiga N, Raanani P, Bairey O, Benjamini O, Nagler A, Peer D. (2020) Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics 12(6):E520.

  5. Van de Vyver T, Bogaert B, De Backer L, Joris F, Guagliardo R, Van Hoeck J, Merckx P, Van Calenbergh S, Ramishetti S, Peer D, Remaut K, De Smedt SC, and Raemdonck K (2020) Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner. ACS Nano. 14(4):4774-4791.

  6. Ramishetti S, Hazan-Halevy I, Palakuri R, Chatterjee S, Naidu Gonna S, Dammes N, Freilich I, Kolik Shmuel L, Danino D, and Peer D (2020) A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Adv Mater. 30:e1906128.

  7. Singh MS, Goldsmith M, Thakur K, Chatterjee S, Landesman-Milo D, Levy T, Kunz-Schughart LA, Barenholz Y, and Peer D (2020) An Ovarian Spheroid Based Tumor Model that Represents Vascularized Tumors and Enables the Investigation of Nanomedicine Therapeutics. Nanoscale 23;12(3):1894-1903.

  8. Veiga N, Goldsmith M, Diesendruck Y, Ramishetti S, Rosenblum D, Elinav E, Behlke MA, Benhar I, and Peer D. (2019) Leukocyte-Specific siRNA Delivery Revealing IRF8 as a Potential Anti-Inflammatory Target. J Control Release. 313:33-41.

  9. Gao M, Deng J, Liu F, Fan A, Wang Y, Wu H, Ding D, Kong D, Wang Z, Peer D, and Zhao Y (2019) Triggered Ferroptotic Polymer Micelles for Reversing Multidrug Resistance to Chemotherapy. Biomaterials. 223:119486.

  10. Hazan-Halevy I, Rosenblum D, Ramishetti S, and Peer D (2019) Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles. Methods Mol Biol. 1974:151-159.

  11. Lusi V, Moore TL, Laurino F, Coclite A, Perreira R, Ferreira M1, Rizzuti I, Palomba R, Zunino P, Duocastella M4, Mizrahy S, Peer D, Decuzzi P (2019) A Tissue Chamber Chip for Assessing Nanoparticle Mobility in the Extravascular Space. Biomed Microdevices. 21(2):41.

  12. Edri R, Gal I, Noor N, Harel T, Fleischer S, Adadi N, Green O, Shabat D, Heller L, Shapira A, Gat-Viks I, Peer D, and Dvir T (2019) Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants. Adv Mater. 31(1):e1803895.

This guy hasn’t plasmids anything yet.

Hot plasmids

This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud